Translational biology of osteosarcoma

Kansara, Maya; Teng, Michele W.; Smyth, Mark J.; Thomas, David M.

doi:10.1038/nrc3838

Cited by 1,294Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsCancer Immunotherapy and Biomarkers

Translational biology of osteosarcoma

Kansara, Maya, Teng, Michele W., Smyth, Mark J., Thomas, David M.·2014·Nature Reviews Cancer

DOI 10.1038/nrc3838

Open this paper in CoChat — free account

Abstract

For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.

Integrity signals

Registry

Crossref · 10.1038/nrc3838

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

One proposal is that osteosarcoma begins when osteoblastic lineage cells transform malignantly at different differentiation stages, with pathways including Notch, Wnt, and RTK promoting uncontrolled proliferation.
“Osteosarcoma cells are thought to originate from the malignant transformation of cells within the osteoblastic lineage at any stage of differentiation, which is controlled by numerous cellular signalling pathways (for example, Notch, Wnt and RTK) that can initiate uncontrolled proliferation 202,203,204,205 .”
From Osteosarcoma (2022) · cites this paper as [202]

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Self-citation
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · see citing works
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · see citing works
WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
Fletcher, C. D. �., Bridge, J., Hogendoorn, P. C. W., & Mertens, F. (2013) · Cited by 3,072 · see citing works
WHO classification of tumours of soft tissue and bone
Fletcher, C. D. �. (2013) · Cited by 2,874 · see citing works
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · see citing works
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712 · see citing works
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · see citing works
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358 · see citing works
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · see citing works
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203 · see citing works
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works
Alternative lengthening of telomeres: models, mechanisms and implications
Cesare, A. J., & Reddel, R. R. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2763 · Cited by 1,022 · see citing works
Requirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996 · see citing works
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A. A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 899 · see citing works
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works
Self-citation
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · see citing works
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752 · see citing works
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · see citing works
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H. I., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 719 · see citing works
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717 · see citing works
Isolation and Characterization of MC3T3-E1 Preosteoblast Subclones with Distinct In Vitro and In Vivo Differentiation/Mineralization Potential
Wang, D., Christensen, K., Chawla, K., Xiao, G., Krebsbach, P. H., & Franceschi, R. T. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.6.893 · Cited by 666 · see citing works
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 616 · see citing works
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint
Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 589 · see citing works
Cell biology of the osteoclast
Roodman, G. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00061-2 · Cited by 571 · see citing works
Osteoimmunology: Interactions of the Bone and Immune System
Lorenzo, J., Horowitz, M. C., & Choi, Y. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0038 · Cited by 566 · see citing works
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563 · see citing works
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. M. M. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 482 · see citing works
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468 · see citing works
The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).
COLEY, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 425 · see citing works
Bloom’s Syndrome
GERMAN, J. L. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30101-3 · Cited by 423 · see citing works
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422 · see citing works
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.
Hansen, M. F., Koufos, A., Gallie, B. L., Phillips, R. A., Fodstad, Ø., Brögger, A., Gedde‐Dahl, T., & Cavenee, W. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6216 · Cited by 414 · see citing works
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21335 · Cited by 376 · see citing works
Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose
Vahle, J. L., Long, G. G., Sandusky, G. E., Westmore, M. S., Ma, Y. L., & Sato, M. (2004) · Toxicologic Pathology · doi:10.1080/01926230490462138 · Cited by 376 · see citing works
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359 · see citing works
Association Between Osteosarcoma and Deleterious Mutations in the RECQL4 Gene in Rothmund-Thomson Syndrome
Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338 · see citing works
Bloom's syndrome. XX. The first 100 cancers
GERMAN, J. L. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00336-6 · Cited by 318 · see citing works
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients
Wang, L. L., Levy, M. L., Lewis, R. A., Chintagumpala, M., Lev, D., Rogers, M., & Plon, S. E. (2001) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20010722)102:1 · Cited by 316 · see citing works
Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma
Gorlick, R. G., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 301 · see citing works
Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., & Sakai, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7786 · Cited by 289 · see citing works
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 289 · see citing works
Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Cultures of Human Bone Cells
Gronthos, S., Zannettino, A. C. W., Graves, S. E., Ohta, S., Hay, S. J., & Simmons, P. J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.47 · Cited by 281 · see citing works
Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions
Quinn, J. M. W., Itoh, K., Udagawa, N., Häusler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1787 · Cited by 278 · see citing works
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P., Simmons, P. J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37175 · Cited by 272 · see citing works
Self-citation
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245 · see citing works
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245 · see citing works
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D’Amato, G. Z., Blay, J., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 244 · see citing works
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243 · see citing works
Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review
Lauper, J. M., Krause, A. J., Vaughan, T. L., & Monnat, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059709 · Cited by 234 · see citing works
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233 · see citing works
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide
MacEwen, E. G., Kurzman, I. D., ROSENTHAL, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 227 · see citing works
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226 · see citing works
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Luduec, J.-B. L., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S. I., Heller, G., Dupont, B., Cheung, N. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 226 · see citing works
Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma
Toguchida, J., Ishizaki, K., Sasaki, M. S., Nakamura, Y., Ikenaga, M., Kato, M. V., Sugimot, M., Kotoura, Y., & Yamamuro, T. (1989) · Nature · doi:10.1038/338156a0 · Cited by 215 · see citing works
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L. J., Wang, Z., Gastier, J. M., Gorlick, R. G., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 200 · see citing works
Self-citation
Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases
Siitonen, H. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg306 · Cited by 196 · see citing works
Cancer in children and adolescents in Europe: Developments over 20 years and future challenges
Pritchard‐Jones, K., Kaatsch, P., Steliarova‐Foucher, E., Stiller, C. A., & Coebergh, J. W. W. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.006 · Cited by 195 · see citing works
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Gorlick, R. G., Anderson, P. M., Andrulis, I. L., Arndt, C., Beardsley, G. P., Bernstein, M. L., Bridge, J. A., Cheung, N. V., Dome, J. S., Ebb, D. H., et al. (2003) · PubMed · Cited by 194 · see citing works
Exomics and immunogenics
Champiat, S., Ferté, C., Lebel‐Binay, S., Eggermont, A. M. M., & Soria, J. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192 · see citing works
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood
Vu, B. L., de Vathaire, F., Shamsaldin, A., Hawkins, M. M., Grimaud, E., Hardiman, C., Diallo, I., Vassal, G., Bessa, E., Campbell, S., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980729)77:3 · Cited by 190 · see citing works
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
Collins, M. L., Wilhelm, M., Conyers, R. K., Herschtal, A., Whelan, J. S., Bielack, S., Kager, L., Kühne, T., Sydes, M. R., Gelderblom, H. A. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8598 · Cited by 186 · see citing works
Self-citation
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S., & Wu, C. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0022 · Cited by 185 · see citing works
Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas
Scheel, C., Schaefer, K., Jauch, A. S., Keller, M., Wai, D., Brinkschmidt, C., van Valen, F., Boecker, W., Dockhorn‐Dworniczak, B., & Poremba, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204493 · Cited by 181 · see citing works
Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma
Bernthal, N. M., Federman, N. C., Eilber, F. R., Nelson, S. D., Eċkardt, J. J., Eilber, F. C., & Tap, W. D. (2012) · Cancer · doi:10.1002/cncr.27651 · Cited by 179 · see citing works
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
Meyers, P. A., Healey, J. H., Chou, A. J., Wexler, L. H., Merola, P. R., Morris, C. D., LaQuaglia, M. P., Kellick, M. G., Abramson, S. J., & Gorlick, R. G. (2010) · Cancer · doi:10.1002/cncr.25744 · Cited by 177 · see citing works
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 Genes and Their Prognostic Implications in Osteosarcoma and Ewing Sarcoma
Tsuchiya, T., Sekine, K., Hinohara, S.-I., Namiki, T., Nobori, T., & Kaneko, Y. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00255-1 · Cited by 177 · see citing works
Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit, A. J., & Fidler, I. J. (1982) · PubMed · Cited by 171 · see citing works
Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B
Karlsson, E. K., Sigurðsson, S., Ivansson, E. L., Thomas, R. J., Elvers, I., Wright, J. B., Howald, C., Tonomura, N., Perloski, M., Swofford, R., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-12-r132 · Cited by 171 · see citing works
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice
Ory, B., Heymann, M., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005) · Cancer · doi:10.1002/cncr.21530 · Cited by 169 · see citing works
The response of bone to mechanical loading and disuse: Fundamental principles and influences on osteoblast/osteocyte homeostasis
Skerry, T. M. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.02.028 · Cited by 166 · see citing works
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
Chen, W., Cooper, T. K., Zahnow, C. A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J. E., Gökgöz, N., Wunder, J. S., Andrulis, I. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.030 · Cited by 162 · see citing works
RecQ Helicases: Conserved Guardians of Genomic Integrity
Larsen, N. B., & Hickson, I. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5037-5_8 · Cited by 161 · see citing works
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
Weigel, B. J., Malempati, S., Reid, J. M., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M., Villaluna, D., Adamson, P. C., & Blaney, S. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24605 · Cited by 161 · see citing works
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157 · see citing works
Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site
Ulaner, G. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg034 · Cited by 154 · see citing works
Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 149 · see citing works
p53 and MDM2 alterations in osteosarcomas
Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8 · Cited by 147 · see citing works
Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma
Lau, C. C., Harris, C. P., Lu, X., Perlaky, L., Gogineni, S. K., Chintagumpala, M., Hicks, J. M., Johnson, M. E., Davino, N. A., Huvos, A. G., et al. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10291 · Cited by 146 · see citing works
Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
Jeys, L. M., Grimer, R. J., Carter, S. R., Tillman, R. M., & Abudu, A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9483-8 · Cited by 145 · see citing works
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
Heymann, D., Ory, B., Blanchard, F., Heymann, M., Coipeau, P., Charrier, C., Couillaud, S., Thiery, J. P., Gouin, F., & Rédiní, F. (2005) · Bone · doi:10.1016/j.bone.2005.02.020 · Cited by 142 · see citing works
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Gökgöz, N., Parkes, R. K., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 140 · see citing works
Genomic mechanisms and measurement of structural and numerical instability in cancer cells
Bayani, J., Selvarajah, S., Maire, G., Vukovic, B., Al-Romaih, K. I., Zieleńska, M., & Squire, J. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.006 · Cited by 139 · see citing works
Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling
Sadiković, B., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Squire, J. A., & Zieleńska, M. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp117 · Cited by 138 · see citing works
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Navid, F., Santana, V. M., & Barfield, R. C. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054167 · Cited by 135 · see citing works
Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance
Chang, H. J., Yoo, B. C., Lim, S., Jeong, S., Kim, W. H., & Park, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1912 · Cited by 134 · see citing works
Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma
Rubin, E. M., Guo, Y., Tu, K., Xie, J., Zi, X., & Hoang, B. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0147 · Cited by 132 · see citing works
New concepts on the immune modulation mediated by mesenchymal stem cells
Bunnell, B. A., Betancourt, A. M., & Sullivan, D. E. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt34 · Cited by 132 · see citing works
Gene amplifications in osteosarcoma—CGH microarray analysis
Atiye, J., Wolf, M., Kaur, S., Monni, O. M., Böhling, T., Kivioja, A., Tas, É., Serra, M., Tarkkanen, M., & Knuutila, S. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20120 · Cited by 130 · see citing works
Stature of young people with malignant bone tumors
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10437 · Cited by 129 · see citing works
High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25A
Vijayakumar, S., Liu, G., Rus, I. A., Yao, S., Chen, Y., Akiri, G., Grumolato, L., & Aaronson, S. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.010 · Cited by 128 · see citing works
Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma
Yang, J., Yang, D., Sun, Y. K., Sun, B., Wang, G., Trent, J. C., Araujo, D. M., Chen, K., & Zhang, W. (2011) · Cancer · doi:10.1002/cncr.26116 · Cited by 125 · see citing works
Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
Gökgöz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8 · Cited by 125 · see citing works
CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons
Guo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2 · Cited by 120 · see citing works
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma
Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114 · see citing works
Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD 2/ GD 3
Shibuya, H., Hamamura, K., Hotta, H., Matsumoto, Y., Nishida, Y., Hattori, H., Furukawa, K., Ueda, M., & Furukawa, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02344.x · Cited by 110 · see citing works
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Pignochino, Y., Dell’Aglio, C., Basiricò, M., Capozzi, F., Soster, M., Marchiò, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2293 · Cited by 107 · see citing works
Bone sarcomas in Paget disease: a study of 85 patients.
Smith, J. J., Botet, J. F., & Yeh, S. D. J. (1984) · Radiology · doi:10.1148/radiology.152.3.6235535 · Cited by 106 · see citing works
Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma
Kresse, S. H., Rydbeck, H., Skårn, M., Namløs, H. M., Barragan-Polania, A. H., Cleton-Jansen, A., Serra, M., Liestøl, K., Hogendoorn, P. C. W., Hovig, E. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048262 · Cited by 106 · see citing works
Genome-wide association studies in common cancers—what have we learnt?
Varghese, J. S., & Easton, D. F. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.03.012 · Cited by 103 · see citing works
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
Freeman, S. S., Allen, S. W., Ganti, R., Wu, J., Ma, J., Su, X., Neale, G. A. M., Dome, J. S., Daw, N. C., & Khoury, J. D. (2008) · Cancer · doi:10.1002/cncr.23782 · Cited by 102 · see citing works
Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13–15: A combined cytogenetic and comparative genomic hybridization study
Szymanska, J., Mandahl, N., Mertens, F., Tarkkanen, M., Karaharju, E. O., & Knuutila, S. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199605)16:1 · Cited by 102 · see citing works
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP
Watanabe, K., Okamoto, K., & Yonehara, S. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401507 · Cited by 102 · see citing works
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Molyneux, S. D., Grappa, M. A. D., Beristain, A. G., McKee, T. D., Wai, D., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42391 · Cited by 98 · see citing works
Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
Karbach, J., Neumann, A., Brand, K., Wahle, C., Siegel, E., Maeurer, M. J., Ritter, E., Tsuji, T., Gnjatic, S., Old, L. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1116 · Cited by 98 · see citing works
Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program
Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., Wu, J., & Smith, M. A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22367 · Cited by 97 · see citing works
Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic
Cai, Y., Cai, T., & Chen, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24708 · Cited by 96 · see citing works
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
Kresse, S. H., Ohnstad, H. O., Paulsen, E. B., Bjerkehagen, B., Szuhai, K., Serra, M., Schaefer, K., Myklebost, O., & Meza‐Zepeda, L. A. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20675 · Cited by 96 · see citing works
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
Kuijjer, M. L., Peterse, E. F. P., van den Akker, B. E., Bruijn, I. H. B., Serra, M., Meza‐Zepeda, L. A., Myklebost, O., Hassan, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-245 · Cited by 95 · see citing works
Insulinlike Growth Factor I: A Potent Mitogen for Human Osteogenic Sarcoma
Pollak, M., Polychronakos, C., & Richard, M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.4.301 · Cited by 94 · see citing works
Physiology of Bone
Grabowski, P. (2009) · Endocrine development · doi:10.1159/000223687 · Cited by 89 · see citing works
Clinicopathologic Analysis of HER-2/neu Immunoexpression among Various Histologic Subtypes and Grades of Osteosarcoma
Kilpatrick, S. E., Geisinger, K. R., King, T. S., Sciarrotta, J., Ward, W. G., Gold, S., & Bos, G. D. (2001) · Modern Pathology · doi:10.1038/modpathol.3880474 · Cited by 88 · see citing works
Cell Cycle Regulator Gene CDC5L , a Potential Target for 6p12-p21 Amplicon in Osteosarcoma
Lu, X., Lu, Y., Zhao, Y., Jaeweon, K., Kang, J., Li, X., Ge, G., Meyer, R., Perlaky, L., Hicks, J. M., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2115 · Cited by 86 · see citing works
RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcoma
Lee, J. A., Jung, J. S., Kim, D. H., Lim, J. S., Kim, M. S., Kong, C., Song, W. S., Cho, W. H., Jeon, D., Lee, S., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22720 · Cited by 83 · see citing works
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 82 · see citing works
Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher, I., Birner, P., Trieb, K., Träxler, M., Lang, S., & Chott, A. (2003) · Modern Pathology · doi:10.1097/01.mp.0000043522.76788.0a · Cited by 81 · see citing works
Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group
Arndt, C. A. S., Koshkina, N., Inwards, C. Y., Hawkins, D. S., Krailo, M., Villaluna, D., Anderson, P. M., Goorin, A. M., Blakely, M. L., Bernstein, M. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0662 · Cited by 79 · see citing works
Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells
Mu, X., Isaac, C. E., Greco, N., Huard, J., & Weiss, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00143 · Cited by 77 · see citing works
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation
Kansara, M., Leong, H. S., Lin, D., Popkiss, S., Pang, P., Garsed, D. W., Walkley, C. R., Cullinane, C. M., Ellul, J., Haynes, N. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70559 · Cited by 76 · see citing works
Self-citation
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75 · see citing works
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas
Entz‐Werlé, N., Stoetzel, C., Marec‐Bérard, P., Kalifa, C., Brugière, L., Pacquement, H., Schmitt, C., Tabone, M., Gentet, J., Quillet, R., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21068 · Cited by 75 · see citing works
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Himoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., et al. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0795-1 · Cited by 74 · see citing works
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
Yu, X., Wu, T. Y., Xiang, Y., Wei-ping, R. E. N., Zhou, Z. B., Sun, Y., & Zhang, C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1019-1 · Cited by 72 · see citing works
Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma
van Dartel, M., Cornelissen, P. W. A., Redeker, S., Tarkkanen, M., Knuutila, S., Hogendoorn, P. C. W., Westerveld, A., Gomes, I., Bras, J., & Hulsebos, T. J. M. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00627-1 · Cited by 70 · see citing works
Cancer‐germline gene expression in pediatric solid tumors using quantitative real‐time PCR
Jacobs, J. F. M., Brasseur, F., de Kaa, C. A. H., van de Rakt, M. W. M. M., Figdor, C. G., Adema, G. J., Hoogerbrugge, P. M., Coulie, P. G., & de Vries, I. J. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22118 · Cited by 69 · see citing works
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo
Hingorani, P., Zhang, W., Gorlick, R. G., & Kolb, E. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1657 · Cited by 68 · see citing works
Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma
Li, Y., Meng, G., & Guo, Q. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.03.013 · Cited by 67 · see citing works
Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
Worth, L. L., Jia, S.-F., Zhou, Z., Chen, L., & Kleinerman, E. S. (2000) · PubMed · Cited by 65 · see citing works
Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma
Koshkina, N. V., Khanna, C., Mendoza, A., Guan, H., DeLauter, L., & Kleinerman, E. S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0007 · Cited by 64 · see citing works
The Folate Receptor α Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate
Yang, R. R., Kolb, E. A., Qin, J., Chou, A. J., Sowers, R. S., Hoang, B. H., Healey, J. H., Huvos, A. G., Meyers, P. A., & Gorlick, R. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1343 · Cited by 64 · see citing works
Recurrent RECQL4 Imbalance and Increased Gene Expression Levels Are Associated with Structural Chromosomal Instability in Sporadic Osteosarcoma
Maire, G., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Zieleńska, M., & Squire, J. A. (2009) · Neoplasia · doi:10.1593/neo.81384 · Cited by 63 · see citing works
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
Schwinger, W., Klass, V., Benesch, M., Lackner, H., Dornbusch, H. J., Sovinz, P., Moser, A., Schwantzer, G., & Urban, C. H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi226 · Cited by 63 · see citing works
Antiproliferative and proapoptotic activities of new pyrazolo[3,4‐ d ]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
Spreafico, A., Schenone, S., Serchi, T., Orlandini, M., Angelucci, A., Magrini, D., Bernardini, G., Collodel, G., Stefano, A. D., Tintori, C., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-9873com · Cited by 63 · see citing works
C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells
MacEwen, E. G., Kutzke, J., Carew, J., Pastor, J., Schmidt, J. A., Tsan, R. Z., Thamm, D. H., & Radinsky, R. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1025404603315 · Cited by 62 · see citing works
Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma
Fletcher (2009) · International Journal of Oncology · doi:10.3892/ijo_00000390 · Cited by 62 · see citing works
Untitled work
(2001) · PubMed · Cited by 61 · see citing works
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
Moore, C. E., Eslin, D. E., Levy, A., Roberson, J. R., Giusti, V., & Sutphin, R. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22673 · Cited by 60 · see citing works
Cytotoxic T-lymphocyte Antigen-4 Polymorphisms and Susceptibility to Osteosarcoma
Liu, Y., He, Z., Feng, D., Shi, G., Gao, R., Wu, X., Song, W., & Yuan, W. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1269 · Cited by 60 · see citing works
Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone, S., Mutsuura, S., Ogawara, M., & Tsubura, E. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.2105 · Cited by 59 · see citing works
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Lockwood, W. W., Stack, D., Morris, T., Grehan, D., O’Keane, C., Stewart, G. L., Cumiskey, J., Lam, W. L., Squire, J. A., Thomas, D. M., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.020 · Cited by 59 · see citing works
Self-citation
COPS3 amplification and clinical outcome in osteosarcoma
Yan, T., Wunder, J. S., Gökgöz, N., Gill, M., Eskandarian, S., Parkes, R. K., Bull, S. B., Bell, R. S., & Andrulis, I. L. (2007) · Cancer · doi:10.1002/cncr.22595 · Cited by 59 · see citing works
Involvement of MET/TWIST/APC Combination or the Potential Role of Ossification Factors in Pediatric High-Grade Osteosarcoma Oncogenesis
Entz‐Werlé, N., Lavaux, T., Metzger, N., Stoetzel, C., Lasthaus, C., Marec‐Bérard, P., Kalita, C., Brugières, L., Pacquement, H., Schmitt, C., et al. (2007) · Neoplasia · doi:10.1593/neo.07367 · Cited by 59 · see citing works
Decitabine-Induced Demethylation of 5′ CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells
Al-Romaih, K. I., Sadiković, B., Yoshimoto, M., Wang, Y. Z., Zieleńska, M., & Squire, J. A. (2008) · Neoplasia · doi:10.1593/neo.08174 · Cited by 58 · see citing works
Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma
Hou, P., Ji, M., Yang, B., Chen, Z., Qiu, J., Shi, X., & Lu, Z. (2006) · Cancer · doi:10.1002/cncr.21762 · Cited by 57 · see citing works
Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma
Yang, J., Cogdell, D. E., Yang, D., Hu, L., Li, H., Zheng, H., Du, X., Pang, Y., Trent, J. C., Chen, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.018 · Cited by 57 · see citing works
Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma
Lin, C. H., Guo, Y., Ghaffar, S., McQueen, P., Pourmorady, J. S., Christ, A. B., Rooney, K., Ji, T., Eskander, R. H., Zi, X., et al. (2013) · Sarcoma · doi:10.1155/2013/147541 · Cited by 57 · see citing works
Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms.
Rathi, A., Virmani, A. K., Harada, K., Timmons, C. F., Miyajima, K., Hay, R. J., Mastrangelo, D., Maitra, A., Tomlinson, G. E., & Gazdar, A. F. (2003) · PubMed · Cited by 54 · see citing works
Aberrant Methylation of p14ARF Gene Correlates with Poor Survival in Osteosarcoma
Oh, J. H., Kim, H.-S., Kim, H., Kim, W. H., & Lee, S. H. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000188063.56091.69 · Cited by 52 · see citing works
Adjuvant Interferon Treatment of Human Osteosarcoma
Strander, H. A., Adamson, U. K. C., Aparisi, T., Broström, L., Cantell, K., Einhorn, S., Hall, K. E., Ingimarsson, S., Nilsonne, U., & Söderberg, G. (1979) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81332-0_7 · Cited by 52 · see citing works
Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma
Yotov, W. V., Hamel, H., Rivard, G.-E., Champagne, M. A., Russo, P., Leclerc, J., Bernstein, M. L., & Levy, E. H. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199909)26:1 · Cited by 52 · see citing works
Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma
KAWANO, M., ITONAGA, I., IWASAKI, T., & TSUMURA, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2224 · Cited by 51 · see citing works
The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
Sampson, E. R., Martin, B., Morris, A. E., Xie, C. L., Schwarz, E. M., O’Keefe, R. J., & Rosier, R. N. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.336 · Cited by 51 · see citing works
Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma
Lo, W. W., Wunder, J. S., Dickson, B. C., Campbell, V. T., McGovern, K., Alman, B. A., & Andrulis, I. L. (2013) · Cancer · doi:10.1002/cncr.28439 · Cited by 50 · see citing works
Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line
Capobianco, E., Mora, A., Sala, D. L., Roberti, A., Zaki, N., Badidi, E., Taranta, M., & Cinti, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095596 · Cited by 50 · see citing works
Pleiotropic effects of bisphosphonates on osteosarcoma
Ohba, T., Cates, J., Cole, H., Slosky, D., Haro, H., Ichikawa, J., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Bone · doi:10.1016/j.bone.2014.03.005 · Cited by 45 · see citing works
Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study
Strander, H. A., Bauer, H. C. F., Brosjö, O., Fernberg, J.-O., Andris Kreicbergs, A., Nilsonne, U., Silfverswärd, C., Signomklao, T., & Söderlund, V. (1995) · Acta Oncologica · doi:10.3109/02841869509127199 · Cited by 45 · see citing works
Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava, S. K., Wang, S., Tong, Y. A., Pirollo, K. F., & Chang, E. H. (1993) · PubMed · Cited by 45 · see citing works
The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases
Gordon, N. B., & Kleinerman, E. S. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_29 · Cited by 43 · see citing works
Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats
Chauvin, C., Philippeau, J.-M., Hémont, C., Hubert, F., Wittrant, Y., Lamoureux, F., Trinité, B., Heymann, D., Rédiní, F., & Josien, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0104 · Cited by 43 · see citing works
Targeting hedgehog‐GLI‐2 pathway in osteosarcoma
Yang, W., Liu, X., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2012) · Journal of Orthopaedic Research® · doi:10.1002/jor.22230 · Cited by 42 · see citing works
Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy
Tanaka, T., Yui, Y., Naka, N., Wakamatsu, T., Yoshioka, K., Araki, N., Yoshikawa, H., & Itoh, K. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9543-8 · Cited by 41 · see citing works
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma
Kelleher, F. C., Cain, J. E., Healy, J. M., Watkins, D. N., & Thomas, D. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.004 · Cited by 40 · see citing works
Self-citation
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédiní, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 40 · see citing works
Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma
Tsukahara, T., Kawaguchi, S., Torigoe, T., Kimura, S., Murase, M., Ichimiya, S., Wada, T., Kaya, M., Nagoya, S., Ishii, T., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00695.x · Cited by 40 · see citing works
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma
Yang, J., Zhao, L., Tian, W., Liao, Z., Zheng, H., Wang, G., & Chen, K. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-56 · Cited by 40 · see citing works
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
Tavanti, E., Sero, V., Vella, S., Fanelli, M., Michelacci, F., Landuzzi, L., Magagnoli, G., Versteeg, R., Picci, P., Hattinger, C. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.643 · Cited by 38 · see citing works
Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptides
Tsuda, N., Murayama, K., Ishida, H., Matsunaga, K., Komiya, S., Itoh, K., & Yamada, A. (2001) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(00)90031-7 · Cited by 36 · see citing works
Physiological and Oncogenic Aurora-A Pathway
Saeki, T., Ouchi, M., & Ouchi, T. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.758 · Cited by 36 · see citing works
Different expression of CD146 in human normal and osteosarcoma cell lines
Schiano, C., Grimaldi, V., Casamassimi, A., Infante, T., Esposito, A., Giovane, A., & Claudio Napoli, A. (2012) · Medical Oncology · doi:10.1007/s12032-012-0158-3 · Cited by 34 · see citing works
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling
Kolb, E. A., Gorlick, R. G., Keir, S. T., Maris, J. M., Lock, R. B., Carol, H., Kurmasheva, R. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23290 · Cited by 32 · see citing works
Inactivation of the RASSF1A in osteosarcoma
Lim, S., Yang, M., Park, J. H., Nojima, T., Hashimoto, H., Unni, K. K., & Park, Y.-K. (2003) · Oncology Reports · doi:10.3892/or.10.4.897 · Cited by 31 · see citing works
Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity
Zhou, Z., Lafleur, E. A., Koshkina, N. V., Worth, L. L., Lester, M. S., & Kleinerman, E. S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0092 · Cited by 31 · see citing works
153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients
Berger, M., Grignani, G., Giostra, A., Ferrari, S. M., Ferraresi, V., Tamburini, A., Cefalo, G., Carnevale‐Schianca, F., Vassallo, E., Picci, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr542 · Cited by 29 · see citing works
Paget disease of bone: Diagnosis and drug therapy
Seton, M. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12142 · Cited by 29 · see citing works
Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes
Mendoza, S., David, H., Gaylord, G. M., & Miller, C. W. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.08.035 · Cited by 28 · see citing works
Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells
Li, Y., Geng, P., Jiang, W., Wang, Y., Yao, J., Xu, L., Liu, J., Huang, L., Su, B., & Chen, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-1634-5 · Cited by 28 · see citing works
Osteoimmunology
Lorenzo, J., & Choi, Y. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00340.x · Cited by 28 · see citing works
Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone
Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K., Nasu, M., & Chihara, K. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199707)172:1 · Cited by 26 · see citing works
Interferon-α enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis
Yuan, X.-W., Zhu, X., Huang, X.-F., Sheng, P.-Y., He, A.-S., Yang, Z.-B., Deng, R., Feng, G., & Liao, W.-M. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00662.x · Cited by 25 · see citing works
Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24 · see citing works
Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells
Li, Y., Huang, Y., Lv, Y., Meng, G., & Guo, Q. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.10.006 · Cited by 24 · see citing works
Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
Eilber, F. R., Townsend, C. M., & Morton, D. L. (1975) · PubMed · Cited by 23 · see citing works
Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis
Johal, S., Ralston, S., & Knight, C. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.2294 · Cited by 23 · see citing works
Werner's Syndrome
Rosén, R., Cimini, R., & Coblentz, D. (1970) · British Journal of Radiology · doi:10.1259/0007-1285-43-507-193 · Cited by 23 · see citing works
Radiation induced extraskeletal osteosarcoma
Logue, J. P., & Cairnduff, F. (1991) · British Journal of Radiology · doi:10.1259/0007-1285-64-758-171 · Cited by 22 · see citing works
Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion
Zhu, X. P., Liu, Z., Peng, A. F., Zhou, Y. F., LONG, X. H., LUO, Q. F., HUANG, S. H., & SHU, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1491 · Cited by 22 · see citing works
Interferons and bone
Beresford, J. N., TAYLOR, G. T., & Triffitt, J. T. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19377.x · Cited by 21 · see citing works
Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma
Vettore, A. L., Sonaglio, de Carvalho, A. C., Toledo, S., Carvalho, de Camargo, B., Salinas-Souza, C., & Petrilli (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44918 · Cited by 21 · see citing works
Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
Ishida, H., Komiya, S., Inoue, Y., Yutani, S., Inoue, A., & Itoh, K. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.29 · Cited by 20 · see citing works
Osteosarcoma
Eilber, F. R., Townsend, C. M., & Morton, D. L. (1975) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197509000-00012 · Cited by 20 · see citing works
The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.
Kosmidis, P., Baxevanis, C. N., Tsavaris, N. B., Papanastasiou, M., Anastasopoulos, E., Bacoyiannis, C., Mylonakis, N., Karvounis, N., Bafaloukos, D. I., & Karabelis, A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1153 · Cited by 19 · see citing works
Antitumor effect of human leukocyte interferon on human osteosarcoma transplanted into nude mice
Masuda, S., Fukuma, H., & Beppu, Y. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90081-0 · Cited by 18 · see citing works
Interferons and osteosarcoma
Strander, H. A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.014 · Cited by 18 · see citing works
MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.
Bielack, S., Smeland, S., Whelan, J., Marina, N. M., Hook, J., Jovic, G., Krailo, M., Butterfaß‐Bahloul, T., Kühne, T., Eriksson, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba10504 · Cited by 18 · see citing works
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies
Liu, Y., Ma, Y., Sun, Z.-Z., Rui, Y., Yin, Q., da Song, S., Wei, X.-M., Liu, J., Liu, X., & Hu, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2165-9 · Cited by 17 · see citing works
Interferon-a enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis
Xiang-wei, Yuan, Xiaofeng, et al. (2007) · 中国药理学报：英文版 · Cited by 17 · see citing works
Novel physiological RECQL4 alternative transcript disclosed by molecular characterisation of Rothmund–Thomson Syndrome sibs with mild phenotype
Colombo, E. A., Fontana, L., Roversi, G., Negri, G., Castiglia, D., Paradisi, M., Zambruno, G., & Larizza, L. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.18 · Cited by 16 · see citing works
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Bielack, S., Smeland, S., Whelan, J. S., Marina, N. M., Hook, J., Jovic, G., Krailo, M., Butterfaß‐Bahloul, T., Kühne, T., Eriksson, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba10504 · Cited by 16 · see citing works

Flagged first, then by citations

1 of the 208 references couldn’t be matched to a known paper.

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
Update on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560 · see citing works
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 475 · see citing works
Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy
Gianferante, D. M., Mirabello, L. J., & Savage, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.16 · Cited by 470 · see citing works
Comparative oncology: what dogs and other species can teach us about humans with cancer
Schiffman, J. D., & Breen, M. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0231 · Cited by 420 · see citing works
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 397 · see citing works
2D MXene‐Integrated 3D‐Printing Scaffolds for Augmented Osteosarcoma Phototherapy and Accelerated Tissue Reconstruction
Pan, S., Yin, J., Yu, L., Zhang, C., Zhu, Y., Gao, Y., & Chen, Y. (2019) · Advanced Science · doi:10.1002/advs.201901511 · Cited by 318 · see citing works
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 300 · see citing works
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 289 · see citing works
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 271 · see citing works
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267 · see citing works
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A.-K., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 265 · see citing works
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253 · see citing works
The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis
Aldiri, I., Xu, B., Wang, L., Chen, X. '., Hiler, D. J., Griffiths, L. M., Valentine, M. B., Shirinifard, A., Thiagarajan, S., Sablauer, A., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.022 · Cited by 249 · see citing works
Molecular genetics of osteosarcoma
Rickel, K., Fang, F., & Tao, J. (2016) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 244 · see citing works
Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
Kager, L., Tamamyan, G., & Bielack, S. (2016) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 240 · see citing works
Review of a new bone tumor therapy strategy based on bifunctional biomaterials
Liao, J., Han, R., Wu, Y., & Qian, Z. (2021) · Bone Research · doi:10.1038/s41413-021-00139-z · Cited by 240 · see citing works
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis
Moriarity, B. S., Otto, G. M., Rahrmann, E. P., Rathe, S. K., Wolf, N. K., Weg, M. T., Manlove, L. A., LaRue, R. S., Temiz, N. A., Molyneux, S. D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3293 · Cited by 238 · see citing works
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237 · see citing works
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233 · see citing works
Bone microenvironment signals in osteosarcoma development
Alfranca, A., Martínez-Cruzado, L., Tornín, J., Abarrategi, A., Amaral, A. T., de Álava, E., Menéndez, P. R., Garcı́a-Castro, J., & Rodrı́guez, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1918-y · Cited by 224 · see citing works
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222 · see citing works
Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
Zhang, Y., Wang, F., Li, M., Yu, Z., Qi, R., Ding, J., Zhang, Z., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700821 · Cited by 221 · see citing works
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma
Liang, C., Li, F., Wang, L., Zhang, Z., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A. B., Liu, J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.015 · Cited by 216 · see citing works
Osteosarcoma: Cells‐of‐Origin, Cancer Stem Cells, and Targeted Therapies
Abarrategi, A., Tornín, J., Martínez-Cruzado, L., Hamilton, A., Martínez‐Campos, E., Rodrigo, J. P., González, M. V., Baldini, N., Garcı́a-Castro, J., & Rodrı́guez, R. (2016) · Stem Cells International · doi:10.1155/2016/3631764 · Cited by 211 · see citing works
In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles
Wang, Y., Wang, J., Hao, H., Cai, M., Wang, S., Ma, J., Li, Y., Mao, C., & Zhang, S. (2016) · ACS Nano · doi:10.1021/acsnano.6b03835 · Cited by 206 · see citing works
MXene-Based Hydrogels Endow Polyetheretherketone with Effective Osteogenicity and Combined Treatment of Osteosarcoma and Bacterial Infection
Yin, J., Han, Q., Zhang, J., Liu, Y., Gan, X., Xie, K., Xie, L., & Deng, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14752 · Cited by 194 · see citing works
H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts
Zhang, Y., Liu, Z., Yang, X., Lu, W., Chen, Y., Lin, Y., Wang, J., Lin, S., & Yun, J. (2020) · Theranostics · doi:10.7150/thno.51245 · Cited by 187 · see citing works
Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187 · see citing works
Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma
Liu, Y., Feng, W., Dai, Y., Bao, M., Yuan, Z., He, M., Qin, Z., Liao, S., He, J., Huang, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709210 · Cited by 184 · see citing works
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
Gomez‐Brouchet, A., Illac, C., Gilhodes, J., Bouvier, C., Aubert, S., Guinebretière, J., Marie, B., Larousserie, F., Entz‐Werlé, N., Pinieux, G. D. B. D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331193 · Cited by 180 · see citing works
TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling
Liu, W., Zhao, Y., Wang, G., Feng, S., Ge, X., Ye, W., Wang, Z., Zhu, Y., Cai, W., Bai, J., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102344 · Cited by 174 · see citing works
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161 · see citing works
3D Printed Wesselsite Nanosheets Functionalized Scaffold Facilitates NIR‐II Photothermal Therapy and Vascularized Bone Regeneration
Yang, C., Ma, H., Wang, Z., Younis, M. R., Liu, C., Wu, C., Luo, Y., & Huang, P. (2021) · Advanced Science · doi:10.1002/advs.202100894 · Cited by 161 · see citing works
GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy
Kim, M., Jung, J.-Y., Choi, S., Lee, H., Morales, L. D., Koh, J.-T., Kim, S. H., Choi, Y.-D., Choi, C., Slaga, T. J., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1239676 · Cited by 160 · see citing works
NIR light-assisted phototherapies for bone-related diseases and bone tissue regeneration: A systematic review
Wan, Z., Zhang, P., Lv, L., & Zhou, Y. (2020) · Theranostics · doi:10.7150/thno.49784 · Cited by 158 · see citing works
Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind, M. F., Wagner, L. M., & Cripe, T. P. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27227 · Cited by 153 · see citing works
Osteosarcoma: Molecular Pathogenesis and iPSC Modeling
Lin, Y.-H., Jewell, B. E., Gingold, J., Lu, L., Zhao, R., Wang, L. L., & Lee, D.-F. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.06.004 · Cited by 150 · see citing works
CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma
Han, Q., Shi, H., & Liu, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.023 · Cited by 149 · see citing works
Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma
Wang, X., Qin, G., Liang, X., Wang, W., Wang, Z., Liao, D., Zhong, L., Zhang, R., Zeng, Y., Wu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14870-4 · Cited by 147 · see citing works
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
Bousquet, M., Noirot, C., Accadbled, F., de Gauzy, J. S., Castex, M., Brousset, P., & Gomez‐Brouchet, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw009 · Cited by 143 · see citing works
LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis
Fu, D., Lu, C., Qu, X., Li, P., Chen, K., Shan, L., & Zhu, X. (2019) · Aging · doi:10.18632/aging.102325 · Cited by 138 · see citing works
Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
Marchandet, L., Lallier, M., Charrier, C., Baud’huin, M., Ory, B., & Lamoureux, F. (2021) · Cancers · doi:10.3390/cancers13040683 · Cited by 137 · see citing works
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Suehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135 · see citing works
Engineering Single‐Atomic Iron‐Catalyst‐Integrated 3D‐Printed Bioscaffolds for Osteosarcoma Destruction with Antibacterial and Bone Defect Regeneration Bioactivity
Wang, L., Yang, Q., Huo, M., Lü, D., Gao, Y., Chen, Y., & Xu, H. (2021) · Advanced Materials · doi:10.1002/adma.202100150 · Cited by 135 · see citing works
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Lamora, A., Talbot, J., Mullard, M., Royer, B. B.-L., Rédiní, F., & Verrecchia, F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110096 · Cited by 131 · see citing works
Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
Verrecchia, F., & Rédiní, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00133 · Cited by 128 · see citing works
Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1.
Liu, C., & Lin, J. (2016) · PubMed Central · Cited by 127 · see citing works
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
Domoto, T., Uehara, M., Bolidong, D., & Minamoto, T. (2020) · Cells · doi:10.3390/cells9061388 · Cited by 127 · see citing works
D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy
Du, C., Zhou, M., Jia, F., Ruan, L., Lu, H., Zhang, J., Zhu, B., Liu, X., Chen, J., Chai, Z., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120642 · Cited by 127 · see citing works
Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR‐Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles
Lu, Y., Li, L., Lin, Z., Li, M., Hu, X., Zhang, Y., Peng, M., Xia, H., & Han, G. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800602 · Cited by 122 · see citing works
Wnt signaling and Loxl2 promote aggressive osteosarcoma
Matsuoka, K., Bakiri, L., Wolff, L. I., Linder, M., Mikels, A. J., Patiño‐García, A., Lecanda, F., Hartmann, C., Sibilia, M. C., & Wagner, E. F. (2020) · Cell Research · doi:10.1038/s41422-020-0370-1 · Cited by 121 · see citing works
Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion
Wang, Z., Li, B., Li, S., Lin, W., Wang, Z., Wang, S., Chen, W., Shi, W., Chen, T., Zhou, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34064-4 · Cited by 121 · see citing works
Multifunctional magnesium incorporated scaffolds by 3D-Printing for comprehensive postsurgical management of osteosarcoma
Long, J., Zhang, W., Chen, Y., Teng, B., Liu, B., Li, H., Yao, Z., Wang, D., Li, L., Yu, X., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120950 · Cited by 119 · see citing works
Calcium phosphate-phosphorylated adenosine hybrid microspheres for anti-osteosarcoma drug delivery and osteogenic differentiation
Zhou, Z., Sun, T., Chen, F., Zuo, D., Wang, H., Hua, Y., Cai, Z., & Tan, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.031 · Cited by 118 · see citing works
Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes
Zhong, L., Liao, D., Li, J., Liu, W., Wang, J., Zeng, C., Wang, X., Cao, Z., Zhang, R., Li, M., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00414-1 · Cited by 116 · see citing works
Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples
Ho, X. D., Phung, P., Le, V. Q., Nguyễn, V. H., Reimann, E., Prans, E., Kõks, G., Maasalu, K., Le, N. T. N., Trinh, L. H., et al. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217736512 · Cited by 114 · see citing works
Tumor microenvironment-responsive hyaluronate-calcium carbonate hybrid nanoparticle enables effective chemotherapy for primary and advanced osteosarcomas
Zhang, Y., Cai, L., Li, D., Lao, Y., Liu, D., Li, M., Ding, J., & Chen, X. (2018) · Nano Research · doi:10.1007/s12274-018-2066-0 · Cited by 114 · see citing works
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
Sundara, Y. T., Kostine, M., Cleven, A. H. G., Bovée, J. V. M. G., Schilham, M. W., & Cleton-Jansen, A.-M. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1925-3 · Cited by 111 · see citing works
Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo
Zhu, J., Yu, W., Liu, B., Wang, Y., Shao, J., Wang, J., Xia, K., Liang, C., Fang, W., Zhou, C., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.488 · Cited by 105 · see citing works
M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
Yadav, P., Subbarayalu, P., Medina, D., Nirzhor, S. S. R., Timilsina, S., Rajamanickam, S., Eedunuri, V. K., Gupta, Y. K., Zheng, S., Abdelfattah, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2106 · Cited by 104 · see citing works
Gut microbial DL-endopeptidase alleviates Crohn’s disease via the NOD2 pathway
Gao, J., Zhao, X., Hu, S., Huang, Z., Hu, M., Jin, S., Lu, B., Sun, K., Wang, Z., Fu, J., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.002 · Cited by 104 · see citing works
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y.-S., Costa-Cabral, S., Frankum, J. R., Gulati, A., Holme, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.023 · Cited by 103 · see citing works
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 103 · see citing works
Activation of hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via Wnt/β-Catenin
Deng, Q., Li, P., Che, M., Liu, J., Biswas, S., Ma, G., He, L., Wei, Z., Zhang, Z., Yang, Y., et al. (2019) · eLife · doi:10.7554/elife.50208 · Cited by 103 · see citing works
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31154 · Cited by 100 · see citing works
Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3
Sun, J., Wang, X., Fu, C., Wang, X., Zou, J., Hua, H., & Bi, Z. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-3975-1 · Cited by 99 · see citing works
Genome‐wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma
Smida, J., Xu, H., Zhang, Y., Baumhoer, D., Ribi, S., Kovac, M. B., von Luettichau, I., Bielack, S., O’Leary, V. B., Leib‐Mösch, C., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30778 · Cited by 98 · see citing works
Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells
Shao, X., Xiang, S., Chen, Y., Zhang, N., Cao, J., Zhu, H., Yang, B., Zhou, Q., Ying, M., & He, Q. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0262-4 · Cited by 98 · see citing works
Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease
Chen, Y., Wu, X., Li, J., Jiang, Y., Xu, K., & Su, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.909408 · Cited by 96 · see citing works
Advances in emerging drugs for osteosarcoma
Hattinger, C. M., Fanelli, M., Tavanti, E., Vella, S., Ferrari, S. M., Picci, P., & Serra, M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051965 · Cited by 94 · see citing works
Exosomal miR-1228 From Cancer-Associated Fibroblasts Promotes Cell Migration and Invasion of Osteosarcoma by Directly Targeting SCAI
Wang, J., Wu, X., Xiao-juan, G., & Jiang, X. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15336368805108 · Cited by 94 · see citing works
Controlled Delivery of Curcumin and Vitamin K2 from Hydroxyapatite-Coated Titanium Implant for Enhanced in Vitro Chemoprevention, Osteogenesis, and in Vivo Osseointegration
Sarkar, N., & Bose, S. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b22474 · Cited by 94 · see citing works
Fabrication of a hydroxyapatite-PDMS microfluidic chip for bone-related cell culture and drug screening
Tang, Q., Li, X., Chen, L., Li, L., Wu, H., Wang, Y., & Shi, X. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.07.016 · Cited by 94 · see citing works
Time‐Sequential and Multi‐Functional 3D Printed MgO 2 /PLGA Scaffold Developed as a Novel Biodegradable and Bioactive Bone Substitute for Challenging Postsurgical Osteosarcoma Treatment
Li, C., Zhang, W., Nie, Y., Du, X., Huang, C., Li, L., Long, J., Wang, X., Tong, W., Qin, L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308875 · Cited by 94 · see citing works
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92 · see citing works
Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma
Huang, X., Chen, J., Wu, W., Yang, W., Zhong, B., Qing, X., & Shao, Z. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.04.009 · Cited by 92 · see citing works
Bone marrow‐derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition
Pietrovito, L., Leo, A., Gori, V., Lulli, M., Parri, M., Becherucci, V., Piccini, L., Bambi, F., Taddei, M. L., & Chiarugi, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12189 · Cited by 91 · see citing works
KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma
Jiang, Y., Li, F., Gao, B., Ma, M., Chen, M., Wu, Y., Zhang, W., Sun, Y., Liu, S., & Shen, H. (2021) · Theranostics · doi:10.7150/thno.53347 · Cited by 91 · see citing works
Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential Prognostic Factor and an Index of Tumor Microenvironment Remodeling in Osteosarcoma
Chen, L., Liu, J.-F., Lu, Y., He, X., Zhang, C., & Zhou, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642144 · Cited by 90 · see citing works
Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity
Liu, K., Liao, Y., Zhou, Z., Zhang, L., Jiang, Y., Lu, H., Xu, T., Dong, Y., Gao, Q., Li, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121383 · Cited by 90 · see citing works
MMP14 in sarcoma: a regulator of tumor microenvironment communication in connective tissues
Gonzalez-Molina, J., Gramolelli, S., Liao, Z., Carlson, J. W., Ojala, P. M., & Lehti, K. (2019) · Cells · doi:10.3390/cells8090991 · Cited by 89 · see citing works
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89 · see citing works
SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT–receptor complex
Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89 · see citing works
Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma
Li, J., Rao, B., Yang, J., Liu, L., Huang, M., Liu, X., Cui, G., Li, C., Han, Q., Yang, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00769 · Cited by 89 · see citing works
The Calcium-Binding Protein S100A6 Accelerates Human Osteosarcoma Growth by Promoting Cell Proliferation and Inhibiting Osteogenic Differentiation
Li, Y., Wagner, E. R., Yan, Z., Wang, Z., Luther, G. A., Jiang, W., Ye, J., Wei, Q., Wang, J., Zhao, L., et al. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438591 · Cited by 88 · see citing works
Dioscin inhibits the growth of human osteosarcoma by inducing G2/M‐phase arrest, apoptosis, and GSDME‐dependent cell death in vitro and in vivo
Ding, Q., Zhang, W., Cheng, C., Mo, F., Chen, L., Peng, G., Cai, X., Wang, J., Yang, S., & Liu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29197 · Cited by 87 · see citing works
RANKL blockade prevents and treats aggressive osteosarcomas
Chen, Y., Grappa, M. A. D., Molyneux, S. D., McKee, T. D., Waterhouse, P. D., Penninger, J. M., & Khokha, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0295 · Cited by 87 · see citing works
Polarization and function of tumor-associated macrophages mediate graphene oxide-induced photothermal cancer therapy
Deng, X., Liang, H., Yang, W., & Shao, Z. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111913 · Cited by 86 · see citing works
Canine sarcomas as a surrogate for the human disease
Gustafson, D. L., Duval, D. L., Regan, D. P., & Thamm, D. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.012 · Cited by 85 · see citing works
From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma
Dean, D. C., Shen, S., Hornicek, F. J., & Duan, Z. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9763-8 · Cited by 85 · see citing works
Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin
He, C., Sun, J., Liu, C., Jiang, Y., & Hao, Y. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0605-x · Cited by 85 · see citing works
Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment
Guan, Y., Zhang, W., Mao, Y., & Li, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02161-1 · Cited by 85 · see citing works
Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance
Feng, H., Wang, J., Chen, W., Shan, B., Guo, Y., Xu, J., Wang, L., Guo, P., & Zhang, Y. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.03.001 · Cited by 84 · see citing works
Expression of Lipid-Metabolism Genes Is Correlated With Immune Microenvironment and Predicts Prognosis in Osteosarcoma
Hu, Q., Lei, T., Hu, Y., & Lei, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.673827 · Cited by 83 · see citing works
The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma
Niu, J., Yan, T., Guo, W., Wang, W., Ren, T., Huang, Y., Zhao, Z., Yu, Y., Chen, C., Huang, Q., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2150003 · Cited by 83 · see citing works
Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets
Jackson, T. M., Bittman, M. E., & Granowetter, L. (2016) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2016.04.002 · Cited by 82 · see citing works
miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14
Ji, Q., Xu, X., Li, L., Goodman, S. B., Bi, W., Xu, M., Xu, Y., Fan, Z., Maloney, W. J., Ye, Q., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.499 · Cited by 82 · see citing works
The Bone Extracellular Matrix as an Ideal Milieu for Cancer Cell Metastases
Kolb, A. D., & Bussard, K. M. (2019) · Cancers · doi:10.3390/cancers11071020 · Cited by 82 · see citing works
The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma
Gao, Y.-Y., Ling, Z., Zhu, Y.-R., Shi, C., Wang, Y., Zhang, X.-Y., Zhang, Z.-Q., Jiang, Q. L., Chen, M., Yang, S., et al. (2021) · Theranostics · doi:10.7150/thno.55655 · Cited by 80 · see citing works

The perplexing role of immuno-oncology drugs in osteosarcoma
Smrke, A., Tam, Y. B., Anderson, P. M., Jones, R. L., & Huang, P. H. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100400 · Cited by 9 · see citing works
Future directions in the treatment of osteosarcoma
Bishop, M. W., Janeway, K. A., & Gorlick, R. G. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 266 · see citing works
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. H., & Guo, W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 573 · see citing works
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270 · see citing works
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123 · see citing works

Authors: Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M.
Affiliations: The University of Melbourne (AU)
The University of Queensland (AU)
Garvan Institute of Medical Research (AU)
Corresponding author: Thomas, David M.
ORCID: Kansara, Maya
Teng, Michele W.
Smyth, Mark J.
Thomas, David M.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-10-16
Volume: 14
Issue: 11
Pages: 722-735
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3838
OpenAlex: W1980088710
Cited by: 1,294
References: 208
Citations by year: 2026: 66 · 2025: 130 · 2024: 134 · 2023: 155 · 2022: 161 · 2021: 173 · 2020: 152 · 2019: 86 · 2018: 66 · 2017: 74 · 2016: 65 · 2015: 29 · 2014: 2
FWCI: 9.69
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: osteosarcoma, bone biology, bone homeostasis, germline predisposition, cancer genomics, chromothripsis, kataegis, genomic instability, targeted therapy, mifamurtide, immune checkpoint inhibitors, adjuvant therapy, metastatic osteosarcoma, translational research
MeSH terms: Animals, Antineoplastic Agents, Bone Development, Humans, Osteosarcoma, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Translational biology of osteosarcoma

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks